Evidence map›Paper›PMID 30467285›Full record

ArticleMolecules (Basel, Switzerland)2018

Modular Synthesis and Biological Investigation of 5-Hydroxymethyl Dibenzyl Butyrolactones and Related Lignans.

Samuel J Davidson, Lisa I Pilkington, Nina C Dempsey-Hibbert, Mohamed El-Mohtadi, Shiying Tang, Thomas Wainwright, Kathryn A Whitehead, David Barker

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Lignans.Molecules (Basel, Switzerland) · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Samuel J DavidsonSchool of Chemical Sciences, University of Auckland, Aucklamd 1010, New Zealand. sdav134@aucklanduni.ac.nz.
Lisa I PilkingtonSchool of Chemical Sciences, University of Auckland, Aucklamd 1010, New Zealand. lisa.pilkington@auckland.ac.nz.ORCID 0000-0002-9292-3261
Nina C Dempsey-HibbertSchool of Healthcare Science, Manchester Metropolitan University, Manchester M1 5GD, UK. N.Dempsey-Hibbert@mmu.ac.uk.
Mohamed El-MohtadiSchool of Healthcare Science, Manchester Metropolitan University, Manchester M1 5GD, UK. MOHAMED.EL-MOHTADI@stu.mmu.ac.uk.
Shiying TangSchool of Healthcare Science, Manchester Metropolitan University, Manchester M1 5GD, UK. SHIYING.TANG@stu.mmu.ac.uk.
Thomas WainwrightSchool of Healthcare Science, Manchester Metropolitan University, Manchester M1 5GD, UK. thomas.wainwright@stu.mmu.ac.uk.
Kathryn A WhiteheadSchool of Healthcare Science, Manchester Metropolitan University, Manchester M1 5GD, UK. K.A.Whitehead@mmu.ac.uk.
David BarkerSchool of Chemical Sciences, University of Auckland, Aucklamd 1010, New Zealand. d.barker@auckland.ac.nz.ORCID 0000-0002-3425-6552

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dibenzyl butyrolactone lignans are well known for their excellent biological properties, particularly for their notable anti-proliferative activities. Herein we report a novel, efficient, convergent synthesis of dibenzyl butyrolactone lignans utilizing the acyl-Claisen rearrangement to stereoselectively prepare a key intermediate. The reported synthetic route enables the modification of these lignans to give rise to 5-hydroxymethyl derivatives of these lignans. The biological activities of these analogues were assessed, with derivatives showing an excellent cytotoxic profile which resulted in programmed cell death of Jurkat T-leukemia cells with less than 2% of the incubated cells entering a necrotic cell death pathway.

Indexed as

4-ButyrolactoneCell SurvivalFuransHumansJurkat CellsLactonesLignansMolecular StructureStereoisomerism4-ButyrolactoneFuransLactonesLignansacyl-Claisenanti-proliferativedibenzyl butyrolactoneslignansstereoselective synthesis

Identifiers

PMID30467285
PMCPMC6321111

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.